ABUS
Price
$3.52
Change
+$0.01 (+0.28%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
673.05M
27 days until earnings call
IDYA
Price
$15.56
Change
-$0.79 (-4.83%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
1.36B
39 days until earnings call
Ad is loading...

ABUS vs IDYA

Header iconABUS vs IDYA Comparison
Open Charts ABUS vs IDYABanner chart's image
Arbutus Biopharma
Price$3.52
Change+$0.01 (+0.28%)
Volume$35.26K
Capitalization673.05M
IDEAYA Biosciences
Price$15.56
Change-$0.79 (-4.83%)
Volume$20.67K
Capitalization1.36B
ABUS vs IDYA Comparison Chart
Loading...
ABUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABUS vs. IDYA commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABUS is a Buy and IDYA is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (ABUS: $3.52 vs. IDYA: $15.57)
Brand notoriety: ABUS and IDYA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABUS: 184% vs. IDYA: 154%
Market capitalization -- ABUS: $673.05M vs. IDYA: $1.36B
ABUS [@Biotechnology] is valued at $673.05M. IDYA’s [@Biotechnology] market capitalization is $1.36B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABUS’s FA Score shows that 0 FA rating(s) are green whileIDYA’s FA Score has 0 green FA rating(s).

  • ABUS’s FA Score: 0 green, 5 red.
  • IDYA’s FA Score: 0 green, 5 red.
According to our system of comparison, ABUS is a better buy in the long-term than IDYA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABUS’s TA Score shows that 7 TA indicator(s) are bullish while IDYA’s TA Score has 4 bullish TA indicator(s).

  • ABUS’s TA Score: 7 bullish, 3 bearish.
  • IDYA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ABUS is a better buy in the short-term than IDYA.

Price Growth

ABUS (@Biotechnology) experienced а +7.49% price change this week, while IDYA (@Biotechnology) price change was -10.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.91%. For the same industry, the average monthly price growth was -11.19%, and the average quarterly price growth was -14.86%.

Reported Earning Dates

ABUS is expected to report earnings on May 01, 2025.

IDYA is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-8.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($1.36B) has a higher market cap than ABUS($673M). ABUS YTD gains are higher at: 7.339 vs. IDYA (-36.381). ABUS has higher annual earnings (EBITDA): -75.14M vs. IDYA (-323.14M). IDYA has more cash in the bank: 676M vs. ABUS (128M). ABUS has less debt than IDYA: ABUS (1.45M) vs IDYA (19.2M). IDYA (7M) and ABUS (6.74M) have equivalent revenues.
ABUSIDYAABUS / IDYA
Capitalization673M1.36B49%
EBITDA-75.14M-323.14M23%
Gain YTD7.339-36.381-20%
P/E RatioN/AN/A-
Revenue6.74M7M96%
Total Cash128M676M19%
Total Debt1.45M19.2M8%
FUNDAMENTALS RATINGS
ABUS vs IDYA: Fundamental Ratings
ABUS
IDYA
OUTLOOK RATING
1..100
5656
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
60
Fair valued
PROFIT vs RISK RATING
1..100
8071
SMR RATING
1..100
9895
PRICE GROWTH RATING
1..100
4794
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (60) in the null industry is in the same range as ABUS (68) in the Biotechnology industry. This means that IDYA’s stock grew similarly to ABUS’s over the last 12 months.

IDYA's Profit vs Risk Rating (71) in the null industry is in the same range as ABUS (80) in the Biotechnology industry. This means that IDYA’s stock grew similarly to ABUS’s over the last 12 months.

IDYA's SMR Rating (95) in the null industry is in the same range as ABUS (98) in the Biotechnology industry. This means that IDYA’s stock grew similarly to ABUS’s over the last 12 months.

ABUS's Price Growth Rating (47) in the Biotechnology industry is somewhat better than the same rating for IDYA (94) in the null industry. This means that ABUS’s stock grew somewhat faster than IDYA’s over the last 12 months.

ABUS's P/E Growth Rating (100) in the Biotechnology industry is in the same range as IDYA (100) in the null industry. This means that ABUS’s stock grew similarly to IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABUSIDYA
RSI
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bullish Trend 2 days ago
71%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
73%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 22 days ago
79%
Bullish Trend 22 days ago
77%
Declines
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 3 days ago
76%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
76%
Aroon
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
82%
View a ticker or compare two or three
Ad is loading...
ABUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EEOFX12.250.11
+0.91%
Pear Tree Essex Environmental Opps Odnry
DLHIX23.89N/A
N/A
Macquarie Healthcare I
FISPX7.51N/A
N/A
Federated Hermes Max-Cap Index IS
UBVLX80.87N/A
N/A
Undiscovered Managers Behavioral Val L
OSCNX20.07N/A
N/A
Invesco Main Street Small Cap R

ABUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABUS has been loosely correlated with ARRY. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ABUS jumps, then ARRY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABUS
1D Price
Change %
ABUS100%
+0.86%
ARRY - ABUS
43%
Loosely correlated
+1.65%
AXON - ABUS
42%
Loosely correlated
+3.18%
IDYA - ABUS
39%
Loosely correlated
+10.70%
VCYT - ABUS
38%
Loosely correlated
+1.93%
ROIV - ABUS
36%
Loosely correlated
+2.34%
More

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with GRI. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then GRI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
+10.70%
GRI - IDYA
54%
Loosely correlated
-17.33%
KRYS - IDYA
51%
Loosely correlated
+3.68%
RCKT - IDYA
50%
Loosely correlated
+8.43%
IMNM - IDYA
49%
Loosely correlated
+7.19%
XENE - IDYA
49%
Loosely correlated
+2.68%
More